Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib for relapsed or refractory pediatric BRAF V600E-positive Langerhans cell histiocytosis
ChiCTR2000032844Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dabrafenib + trametinib in Langerhans cell histiocytosis (LCH), sponsored by Beijing Children's Hospital. Primary endpoints: Overall response rate at 12 months, Conversion rate of plasma cfBRAF-V600E at 12 months and 2 more. Started Nov 2016; status: recruiting.
02
Drugs
dabrafenib + trametinib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2000032844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032844.